文献速递肝病

安慰剂治疗患者荟萃分析:MASH随机对照试验中的治疗脱落率

Meta-Analysis of Placebo-Treated Patients: Dropout Rates From Treatment in MASH Randomised Controlled Trials.
PubMed 文献 · Aliment Pharmacol Ther · 2025-01-14

该荟萃分析纳入截至2024年11月24日发表的60项2-4期MASH随机对照试验、共3230例安慰剂治疗患者,估计汇总脱落率为11.06%(95%CI 9.07至13.42),主要原因为患者选择(4.06%),脱落率随治疗时间延长而增加,试验分期和治疗时长应在未来试验样本量计算中予以考虑。

要点

  • MASH安慰剂对照试验汇总脱落率为11.06%(95%CI 9.07至13.42)。
  • 脱落主因为患者选择(4.06%),不良事件和失访分别为2.41%和1.79%。
  • 3-4期试验脱落率高于2期试验,治疗时间越长脱落率越高。

核心结论

  • MASH随机对照试验中安慰剂脱落率显著,主要归因于患者选择。
  • 未来临床试验计算样本量时应考虑试验分期和治疗时长等因素。

研究设计与样本

  • 检索PubMed和Cochrane数据库截至2024年11月24日的2-4期MASH随机对照试验,纳入含安慰剂组的试验。
  • 脱落定义为意向性治疗分析中纳入但未完成治疗的患者流失。
  • 对随机对照试验进行定性审查以评估预期和观察到的脱落,采用广义线性混合模型估计汇总脱落率。

主要发现

  • 共分析60项随机对照试验、3230例安慰剂治疗的MASH患者。
  • 33项随机对照试验报告了用于估计效应量的脱落率,其中60.6%的预期脱落率高于安慰剂组观察到的脱落率,36.4%低于,3.0%相似。
  • 总体脱落率为11.06%(95%CI 9.07至13.42),3-4期试验高于2期试验。
  • 因不良事件、失访和患者选择导致的脱落率分别为2.41%(95%CI 1.67至3.48)、1.79%(95%CI 1.06至2.99)和4.06%(95%CI 2.97至5.53)。
  • 荟萃回归确定脱落率随治疗时间延长而增加。

临床怎么用

  • 原文结论指出,未来临床试验计算样本量时应考虑试验分期和治疗时长等因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dropout is common and affects the statistical power and randomization balance of randomised controlled trials (RCTs). AIMS: To estimate the dropout rate in RCTs of metabolic dysfunction-associated steatohepatitis (MASH) and to examine factors associated with dropout in placebo-treated participants. METHODS: PubMed and Cochrane databases were searched for phase 2-4 MASH RCTs with placebo arms through November 24, 2024. Dropout was defined as the attrition of patients included in the intention-to-treat analysis but did not complete treatment. RCTs were qualitatively reviewed to assess the expected and observed dropouts. Generalised linear mixed model was used to estimate pooled dropout rates. RESULTS: Sixty RCTs with 3230 placebo-treated participants with MASH were analysed. Thirty-three RCTs reported the dropout rate used to estimate the effect size. Of these, 60.6%, 36.4%, and 3.0% had an expected dropout rate that was higher, lower, and similar, respectively, than the observed dropout rate in the placebo arm. Overall, the dropout rate was 11.06% (95% confidence interval [CI] 9.07 to 13.42), with a higher rate in phase 3-4 trials than in phase 2 trials. The corresponding rates due to adverse events, loss to follow-up and patient choice were 2.41% (95% CI 1.67 to 3.48), 1.79% (95% CI 1.06 to 2.99) and 4.06% (95% CI 2.97 to 5.53), respectively. Meta-regression determined that the dropout rate increased with longer treatment duration. CONCLUSION: Placebo dropout in MASH RCTs is significant, mainly due to patient choice. Factors such as trial phase and treatment duration should be considered when calculating sample size in future clinical trials.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Souza M, Amaral MJM, Lima LCV, et al. Meta-Analysis of Placebo-Treated Patients: Dropout Rates From Treatment in MASH Randomised Controlled Trials. Aliment Pharmacol Ther. 2025. PMID: 39807647. doi:10.1111/apt.18498

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。